Literature DB >> 2784141

IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes.

T J Ferro1, A Johnson, J Everitt, A B Malik.   

Abstract

We investigated the effect of IL-2 in the isolated guinea pig lung perfused with phosphate-buffered Ringer's solution (containing 0.5 g/100 ml albumin and 5.5 mM dextrose) to determine the mechanism of IL-2-induced pulmonary edema. IL-2 (0 to 10,000 U/ml) was added to the perfusate following a 10 min baseline steady-state period. Pulmonary arterial pressure (Ppa), pulmonary capillary pressure (Ppc), and change in lung weight (as a measure of developing pulmonary edema) were recorded at 0, 10, 30, 40, and 60 min. The capillary filtration coefficient (Kf.c), an index of vascular permeability to water, was measured at 30 and 60 min. Infusion of IL-2 increased Ppc (from 3.9 +/- 0.1 cm H2O at baseline to 8.8 +/- 1.1 cm H2O at 60 min for IL-2 at 2000 U/ml, p less than 0.01; and from 3.8 +/- 0.1 cm H2O at baseline to 8.9 +/- 0.6 cm H2O at 60 min for IL-2 at 10,000 U/ml, p less than 0.01. The lung weight also increased (32% at IL-2 concentration of 2000 U/ml, and 26% at IL-2 concentration of 10,000 U/ml) The capillary filtration coefficient did not change with IL-2 infusion. The IL-2 response was prevented using the pulmonary vasodilator, papaverine. The infusion of IL-2 was associated with the generation of thromboxane A2(TxA2) in the effluent perfusate. Inhibition of TxA2 synthetase using Dazoxiben prevented the pulmonary vasoconstriction and edema response to IL-2. In addition, IL-2 had no effect on the transendothelial clearance of 125I-albumin. The results indicate that IL-2 causes pulmonary edema secondary to an increase in Ppc. The response is mediated by IL-2 stimulation of TxA2 generation from the lung.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784141

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.

Authors:  Uzma Fatima; Balvinder Singh; Karthikeyan Subramanian; Purnananda Guptasarma
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

2.  Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.

Authors:  G Acerbis; L Cleris; M Rodolfo; G Parmiani; F Formelli
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2.

Authors:  R Welbourn; G Goldman; L Kobzik; C R Valeri; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1990-12       Impact factor: 12.969

4.  Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis.

Authors:  Cristina Lupu; Andrew D Westmuckett; Glenn Peer; Lacramioara Ivanciu; Hua Zhu; Fletcher B Taylor; Florea Lupu
Journal:  Am J Pathol       Date:  2005-10       Impact factor: 4.307

5.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

6.  Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.

Authors:  I Kurane; B L Innis; S Nimmannitya; A Nisalak; A Meager; J Janus; F A Ennis
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

7.  Interleukin-2 induces early multisystem organ edema mediated by neutrophils.

Authors:  R Welbourn; G Goldman; L Kobzik; I Paterson; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

8.  Therapy with interleukin-2 induces the systemic release of phospholipase-A2.

Authors:  G J Wolbink; C Schalkwijk; J W Baars; J Wagstaff; H van den Bosch; C E Hack
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

9.  Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.

Authors:  D J Deehan; S D Heys; W Simpson; R Herriot; J Broom; O Eremin
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

10.  Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.

Authors:  C Haworth; S M O'Reilly; E Chu; G J Rustin; M Feldmann
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.